Login to Your Account



DEALS AND M&A NEWS

As its lead compound, telotristat etiprate (LX1032), marches toward the goal line, Lexicon Pharmaceuticals Inc. pocketed $23 million up front as part of a potential $145 million licensing deal with Paris-based Ipsen SA to commercialize the drug outside North America and Japan.

BREAKING UP IS HARD TO DO
It's official. The board of directors at Dublin-based Shire plc agreed on Monday with Abbvie Inc. that its proposed $55 billion purchase of the Irish company is not going to happen.
DUBLIN – Abbvie Inc. is walking away from its $55 billion takeover of Shire plc and, potentially, into a whole pile of trouble.
More DEALS AND M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: